NN0365-3769 (Mim8) is a study medicine with the potential to prevent and reduce bleeding in people with haemophilia A (an inherited disorder in which blood does not coagulate properly).
This study will investigate if different doses of Mim8 are safe, and also check how Mim8 behaves in the body.
Twelve different doses will be tested. Participants will only get one of the doses. Which dose participants get is decided by chance. Participants will get a single injection under the skin of the belly by means of a syringe and a needle.
The study will last for about 17 - 21 weeks.
| Condition | Healthy Volunteers - Haemophilia A |
|---|---|
| Treatment | Mim8 B, 10 mg/mL, Mim8 B, 100 mg/mL, Mim8 B, placebo |
| Clinical Study Identifier | NCT05127473 |
| Sponsor | Novo Nordisk A/S |
| Last Modified on | 21 May 2022 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.